Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)

Fiona Simpkins; Alexandra Leary; Lyndsay Willmott; Bradley Monk; Jean-Sebastien Frenel; David Starks; Meena Okera; Angeles Alvarez Secord; David O'Malley; Lainie Martin; Kaissa Ouali; Martin Oehler; Jeffrey Goh; Brian Slomovitz; Peter Lim; Catherine Shannon; Robert Neff; Doris Kim; Hailun Li; Danielle Jandial; Floor Backes

doi:10.1016/j.ygyno.2025.03.060

Back

Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)

Journal article

Peer reviewed

Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)

Fiona Simpkins, Alexandra Leary, Lyndsay Willmott, Bradley Monk, Jean-Sebastien Frenel, David Starks, Meena Okera, Angeles Alvarez Secord, David O'Malley, Lainie Martin, …

Gynecologic oncology, Vol.200, pp.8-9

09/2025

DOI: https://doi.org/10.1016/j.ygyno.2025.03.060

Metrics

1 Record Views

Details

Title: Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)
Creators: Fiona Simpkins
Alexandra Leary
Lyndsay Willmott
Bradley Monk
Jean-Sebastien Frenel
David Starks
Meena Okera
Angeles Alvarez Secord
David O'Malley
Lainie Martin
Kaissa Ouali
Martin Oehler
Jeffrey Goh
Brian Slomovitz
Peter Lim
Catherine Shannon
Robert Neff
Doris Kim
Hailun Li
Danielle Jandial
Floor Backes
Publication Details: Gynecologic oncology, Vol.200, pp.8-9
Identifiers: 991006226263302656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)

Related links

Metrics

Details